

Baxter International Inc.
Key Product Line Sales by Quarter
Period Ending December 31, 2003
(unaudited)

(\$ in millions)	2003					2002					% Growth				
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
BioScience															
Recombinants	244	253	291	337	1,125	232	247	255	265	999	5%	3%	14%	27%	13%
Plasma Proteins ¹	229	230	251	295	1,005	238	241	251	278	1,008	(4%)	(4%)	0%	6%	0%
Antibody Therapy	67	71	77	96	311	76	73	83	86	318	(12%)	(4%)	(8%)	12%	(2%)
Transfusion Therapies ²	134	136	133	150	553	130	131	130	157	548	3%	3%	3%	(4%)	1%
Other ³	66	83	68	60	277	70	40	57	56	223	(5%)	102%	23%	3%	24%
Total BioScience	740	773	820	938	3,271	746	732	776	842	3,096	(1%)	5%	6%	11%	6%
Medication Delivery															
IV Therapies ⁴	248	271	275	306	1,100	223	240	244	275	982	11%	13%	13%	11%	12%
Drug Delivery	161	168	175	195	699	132	134	147	167	580	21%	26%	19%	16%	20%
Electronic Infusion Systems	166	191	199	258	814	166	178	181	232	757	0%	7%	10%	11%	8%
Anesthesia ⁵	181	201	197	229	808	107	147	138	176	568	69%	37%	42%	30%	42%
Other ⁶	94	107	102	114	417	100	106	110	114	430	(6%)	0%	(6%)	1%	(3%)
Total Medication Delivery ⁷	850	938	948	1,102	3,838	728	805	820	964	3,317	17%	17%	16%	14%	16%
Renal															
PD Therapy	301	337	339	367	1,344	300	304	325	333	1,262	0%	11%	4%	10%	6%
HD Therapy	103	111	107	125	446	97	99	106	116	418	6%	12%	1%	8%	7%
Other	3	4	5	5	17	4	5	2	6	17	(34%)	0%	62%	(8%)	(2%)
Total Renal	407	452	451	497	1,807	401	408	433	455	1,697	2%	11%	4%	9%	6%
TOTAL BAXTER	1,997	2,163	2,219	2,537	8,916	1,875	1,945	2,029	2,261	8,110	6%	11%	9%	12%	10%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, plasma-based biosurgery (Tisseel) and other plasma-based products.

² Formerly referred to as Fenwal.

³ Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

⁴ Principally includes intravenous solutions and nutritional products.

⁵ Includes ESI Lederle.

⁶ Principally includes oncology and other hospital-distributed products.

⁷ Sales of pain management products, which were previously included in Anesthesia, are now reported in either Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.